Farxiga Patient Assistance for Low-Income: How to Get Dapagliflozin Free or Cheap

What Does Farxiga Actually Cost Without Help?

Farxiga's retail cash price runs approximately $620 per 30-day supply for either the 5 mg or 10 mg tablet strength. That price reflects the average across major U.S. Pharmacy chains in 2025 and 2026. For a patient managing type 2 diabetes, heart failure, or chronic kidney disease on a fixed income, that figure is simply not sustainable.

Dapagliflozin belongs to the SGLT2 inhibitor drug class. The FDA first approved it in January 2014 for glycemic control in adults with type 2 diabetes [1]. The agency expanded the label in May 2020 to include heart failure with reduced ejection fraction [2] and again in April 2021 for chronic kidney disease [3]. Because it now spans three serious chronic conditions, access problems carry real clinical weight.

Why the Price Is This High

No generic dapagliflozin is available in the United States as of early 2026. AstraZeneca holds the patent and markets Farxiga exclusively. The FDA's database of approved drug products confirms that dapagliflozin tablets (NDA 202293) remain under brand-name exclusivity [1]. Until a generic enters the market, cash-pay patients face the full branded list price.

The Clinical Stakes of Skipping Doses

Patients who ration or stop dapagliflozin face measurable risk. The DAPA-HF trial (N=4,744) showed that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) [4]. The DAPA-CKD trial (N=4,304) showed a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal or cardiovascular death (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [5]. Stopping dapagliflozin to save money is not a trivial tradeoff.

AstraZeneca's AZ&Me Prescription Savings Program

AstraZeneca runs a direct patient assistance program called AZ&Me Prescription Savings. This is the highest-value option for uninsured or underinsured low-income patients and can result in $0 cost for the medication [6].

Who Qualifies

AZ&Me uses a tiered income structure. Uninsured patients with household income at or below 600% of the federal poverty level (FPL) may qualify to receive Farxiga at no charge. In 2025, 600% FPL was approximately $90,840 for a single person and $187,320 for a family of four. AstraZeneca updates these thresholds annually, so verifying the current figures directly at azandme.com before applying is the right step.

Patients who have Medicare Part D but still struggle with cost may qualify for a separate tier of the AZ&Me program. This tier provides medication at a reduced price rather than free, but the savings are still substantial.

How to Apply

1. Download the AZ&Me enrollment form from the AstraZeneca website or request one from your prescriber's office.
2. Have your prescriber complete and sign the clinical section.
3. Submit proof of income (most recent tax return or three recent pay stubs).
4. Mail or fax the completed packet to AstraZeneca's fulfillment center.

Processing typically takes 2 to 4 weeks. Expedited review is available if a patient can document urgent medical need. Once approved, the medication ships directly to the prescriber's office or, in some states, to the patient's home. Approvals are generally valid for 12 months, after which re-enrollment is required.

What to Do While Waiting

AstraZeneca's team can sometimes provide a 30-day bridge supply while the full application is reviewed. Ask the program coordinator explicitly about this option when you call. Your prescriber's office may also have sample packs of Farxiga from AstraZeneca sales representatives that can cover a short gap.

AstraZeneca Savings Card for Commercially Insured Patients

Patients with private insurance (employer-sponsored or individually purchased, not Medicare or Medicaid) can use the AstraZeneca Farxiga savings card to reduce co-pays substantially. The current card brings eligible commercially insured patients to as low as $0 per month, up to a program maximum per year [6].

Income Limits and Restrictions

The commercial savings card does not have an income limit, but it does have categorical restrictions. Patients enrolled in any federal or state government health insurance program, including Medicare, Medicaid, CHIP, TRICARE, or VA benefits, are not eligible. The card is strictly for patients with commercial insurance.

Where to Get the Card

Cards are available at farxiga.com, at participating pharmacies, and through your prescriber. Most cards are now digital and can be loaded into pharmacy apps. Present the card every time you fill the prescription because the discount applies at the point of sale.

Medicare and Medicaid Coverage for Farxiga

Medicare Part D

Farxiga is covered on most Medicare Part D formularies, but tier placement varies by plan. Many plans place it on Tier 3 or Tier 4, meaning cost-sharing can still be significant. The Inflation Reduction Act of 2022 capped Medicare out-of-pocket drug spending at $2,000 per year beginning in 2025, which helps patients who previously hit catastrophic-phase costs [7].

Low-income Medicare beneficiaries may qualify for the Extra Help (Low Income Subsidy) program administered by the Social Security Administration. Extra Help can reduce Part D premiums, deductibles, and co-pays for qualifying individuals. The SSA income threshold for full Extra Help was approximately $22,590 for individuals and $30,660 for couples in 2025 [8]. Applications are available at ssa.gov/extrahelp.

Medicaid

Medicaid coverage of Farxiga depends on the state. Most state Medicaid programs include at least one SGLT2 inhibitor on formulary due to the drug class's cardiovascular and renal outcomes data. Some states require prior authorization, step therapy through metformin first, or documented cardiovascular disease or CKD for dapagliflozin specifically. Your pharmacist can run a real-time eligibility check to see whether your state's Medicaid plan covers Farxiga without prior authorization.

The American Diabetes Association's 2024 Standards of Care explicitly state that "for patients with type 2 diabetes and established cardiovascular disease, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended" [9]. That guideline language supports prior authorization appeals when a payer denies Farxiga for a patient with qualifying comorbidities.

State Pharmaceutical Assistance Programs

More than 35 states operate pharmaceutical assistance programs (PAPs) for residents who are underinsured or who fall into coverage gaps. These are separate from Medicaid and often serve patients who earn too much for Medicaid but too little to afford branded medications.

How State PAPs Work

State programs vary significantly in structure. Some pay the manufacturer directly and route medications through the regular pharmacy. Others issue vouchers or direct subsidies. Income limits, covered drugs, and application processes differ by state.

The National Conference of State Legislatures maintains a database of state pharmaceutical assistance programs. NeedyMeds.org also aggregates both manufacturer and state programs in a searchable format. Because these programs change funding levels and eligibility criteria year to year, checking current status before applying saves time.

States with Notable Programs

States including New Jersey (PAAD), Pennsylvania (PACE), and New York (EPIC) have long-running programs with relatively broad formularies that include SGLT2 inhibitors. Residents of those states should check eligibility before assuming Farxiga is unaffordable.

GoodRx, RxSaver, and Other Discount Cards

Discount cards and apps such as GoodRx, RxSaver, SingleCare, and Blink Health negotiate prices with pharmacy benefit managers and can reduce Farxiga's cash price at participating pharmacies. The discount depends on the pharmacy and changes frequently, but savings of 15% to 25% off the retail price are common.

These programs are useful for patients who do not qualify for AZ&Me and lack commercial insurance. They are generally not combinable with insurance. You pay either the insurance co-pay or the discount card price, whichever is lower.

The table below summarizes the primary access pathways by insurance status:

| Patient Situation | Best First Option | Potential Monthly Cost | |---|---|---| | Uninsured, income <600% FPL | AZ&Me Prescription Savings | $0 | | Commercially insured | AstraZeneca savings card | $0 (up to annual cap) | | Medicare Part D, low income | Extra Help (SSA) + Part D | Reduced co-pay | | Medicare Part D, higher income | Formulary tier appeal or exception | Varies by plan | | Medicaid | State formulary (may need PA) | $0 to small co-pay | | Uninsured, does not qualify for AZ&Me | Discount card (GoodRx, etc.) | $450, $530 estimated |

How to Appeal an Insurance Denial

Insurance denials for Farxiga are common and are often overturned on appeal. The denial most frequently cites either step therapy requirements (the insurer wants you to try a different SGLT2 inhibitor first) or lack of documented indication.

Building a Strong Appeal

Your prescriber's office handles most of the paperwork, but knowing what strengthens the case helps. Appeals that succeed typically include:

• A letter of medical necessity from the prescribing physician citing the specific indication (diabetes, heart failure, or CKD).
• Reference to the ADA 2024 Standards of Care [9] or the 2022 AHA/ACC heart failure guidelines [10], which both support SGLT2 inhibitor use in appropriate patients.
• Documentation of prior medications tried and why alternatives are inadequate. For example, canagliflozin (Invokana) carries a higher risk of lower-limb amputation that may make it inappropriate for individual patients, per the FDA's 2017 black box warning [11].
• Lab data showing eGFR, HbA1c, or ejection fraction that confirms the clinical indication.

Most commercial insurers are required to respond to standard appeals within 30 days and urgent appeals within 72 hours under the Affordable Care Act's internal appeal rules [12].

External Appeals

If an internal appeal fails, all states allow an independent external review. The insurer must abide by the external reviewer's decision. External review requests must typically be filed within 60 days of the final internal denial.

Compounded Dapagliflozin: Not Currently Available

Some patients ask whether compounded dapagliflozin is available as a lower-cost alternative, given that compounded versions of semaglutide and tirzepatide have been widely discussed. As of early 2026, dapagliflozin is not on the FDA's drug shortage list [13], and compounding pharmacies are not permitted to compound copies of commercially available drugs that are not in shortage under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act [14]. A pharmacist or prescriber who offers compounded dapagliflozin outside of an active FDA shortage would be operating outside federal law.

Biosimilar and Generic Outlook

The first generic versions of dapagliflozin are expected to enter the U.S. Market when AstraZeneca's patents expire. Patent expiration timelines are subject to litigation and can shift. The FDA's Orange Book lists active patents for NDA 202293, and patent challenge litigation outcomes will determine when generics launch [1]. When a generic does become available, prices could drop by 70% to 90% based on typical post-exclusivity market patterns seen with other blockbuster drugs.

Patients and prescribers should monitor the FDA's drug approval announcements for any generic dapagliflozin ANDA approvals.

Practical Steps: Getting Farxiga for $0 This Month

Step 1: Determine Your Insurance Status

Run through this sequence before making calls. Are you uninsured? Do you have commercial insurance? Are you on Medicare or Medicaid? Each answer leads to a different program.

Step 2: Contact AstraZeneca or Your Prescriber First

If you are uninsured or underinsured, call AZ&Me at the number listed on azandme.com before paying out of pocket. The enrollment team can assess eligibility on the first call and send forms by email or fax the same day. Your prescriber's office can also initiate this on your behalf.

Step 3: Use the Savings Card at the Pharmacy If You Have Commercial Insurance

Present the savings card (printed or digital) at the pharmacy counter before the pharmacist processes the claim. Do not pay the full co-pay and try to get reimbursed later. The savings card must be applied at the point of sale.

Step 4: Apply for Extra Help If You Have Medicare

The Extra Help application takes about 30 minutes online at ssa.gov or by phone at 1-800-772-1213. Social Security reviews applications within 3 weeks and, if approved, applies the subsidy retroactively to the beginning of the month in which you applied.

Step 5: Ask Your Prescriber to File a Prior Authorization If Needed

Medicaid and some Medicare Part D plans require prior authorization. This is a routine task for most prescriber offices. The ADA 2024 Standards of Care state that "access to medications remains a significant barrier to diabetes management for many patients" [9] and recommend that clinicians actively assist with insurance processes. Your prescriber should not decline to file a PA on your behalf.

Frequently Asked Questions